Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling

Area of Science:

• Cardiology
• Molecular Biology
• Regenerative Medicine

Background:

• Cardiomyocyte remodeling, including dedifferentiation, is implicated in acute myocardial infarction (MI) and chronic dilated cardiomyopathy (DCM).
• The specific mediators and functional consequences of cardiomyocyte dedifferentiation in heart disease remain incompletely understood.

Purpose of the Study:

• To investigate the role of Oncostatin M (OSM) as a mediator of cardiomyocyte dedifferentiation and remodeling in acute MI and chronic DCM.
• To explore the therapeutic potential of modulating OSM signaling in cardiac disease models.

Main Methods:

• Analysis of OSM expression in human DCM patients.
• In vivo studies using mouse models of MI and DCM.
• Treatment with OSM or inhibition of OSM signaling in cardiac disease models.
• Assessment of cardiomyocyte dedifferentiation, stem cell marker expression, and cardiac function.

Main Results:

• Elevated OSM expression and signaling observed in DCM patients and cardiac disease models.
• OSM treatment induced cardiomyocyte dedifferentiation and improved cardiac function post-MI.
• Inhibition of OSM signaling suppressed remodeling post-MI, leading to functional decline.
• Conversely, OSM inhibition improved cardiac performance in a DCM mouse model.

Conclusions:

• OSM is a key mediator of cardiomyocyte dedifferentiation and remodeling in both acute and chronic heart conditions.
• Cardiomyocyte dedifferentiation, initially protective, can become detrimental with sustained OSM activation.
• Targeting OSM signaling presents a potential therapeutic strategy for managing cardiac remodeling and function in heart disease.